Onureg (azacitidine)

pCPA File Number: 21641
Negotiation Status:
Concluded with an LOI
Indication(s):
Acute myeloid leukemia (AML), Maintenance therapy in adult patients who achieved complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following induction therapy with or without consolidation treatment, and who are not eligible for hematopoietic stem cell transplantation (HSCT)
Sponsor/Manufacturer:
Celgene Inc.
CDA-AMC Project Number:
PC0245-000
pCPA Engagement Letter Issued:
Negotiation Process Concluded: